The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwNHL 2018 | iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine
The International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, presented an array of exciting new data in NHL. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, discusses the highlights of day 1 of the meeting with Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, and Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children’s National Health System, Washington, DC. Some of the topics explored by the experts include enhancing T-cell response, expediting our knowledge of biomarkers, and the development of new combination regimens to target different populations of malignant cells.
